Facetten
Zugriff
Einrichtung
Medientyp
- Text 17
Karte
Erscheinungsjahr
Autor/in
- Weisel, Katja
- Dimopoulos, Meletios 3
- Goldschmidt, Hartmut 3
- Ludwig, Heinz 3
- Moreau, Philippe 3
- alle zeigen
Sprache
- Englisch 17
17 Einträge gefunden
-
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
- Raab, Marc S
- Engelhardt, Monika
- Blank, Antje
- Goldschmidt, Hartmut
- Agis, Hermine
- Blau, Igor W
- Einsele, Hermann
-
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma:results from a systematic literature review and network meta-analysis
- Ramasamy, Karthik
- Dhanasiri, Sujith
- Thom, Howard
- Buchanan, Vanessa
- Robinson, Suzanne
- D'Souza, Vijay K
- Weisel, Katja
-
-
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
- Vij, Ravi
- Nath, Rajneesh
- Afar, Daniel E H
- Mateos, Maria Victoria
- Berdeja, Jesus G
- Raab, Marc S
- Guenther, Andreas
-
-
Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis
- Karagiannis, Panagiotis
- Sänger, Lena
- Alsdorf, Winfried
- Weisel, Katja
- Fiedler, Walter
- Kluge, Stefan
- Wichmann, Dominic
-
-
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
- Weisel, Katja
- Majer, Istvan
- DeCosta, Lucy
- Oriol, Albert
- Goldschmidt, Hartmut
- Ludwig, Heinz
- Campioni, Marco
-
-
-
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
- Dimopoulos, Meletios A
- Niesvizky, Ruben
- Weisel, Katja
- Siegel, David S
- Hajek, Roman
- Mateos, María-Victoria
- Cavo, Michele
-
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
- Weisel, Katja
- Dimopoulos, Meletios
- Moreau, Philippe
- Yagci, Munci
- Larocca, Alessandra
- Kanate, Abraham S
- Vural, Filiz
-
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
- Ludwig, Heinz
- Pönisch, Wolfram
- Knop, Stefan
- Egle, Alexander
- Hinke, Axel
- Schreder, Martin
- Lechner, Daniel
-
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- Dimopoulos, Meletios
- Quach, Hang
- Mateos, Maria-Victoria
- Landgren, Ola
- Leleu, Xavier
- Siegel, David
- Weisel, Katja
-
-
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
- Mateos, Maria-Victoria
- Spencer, Andrew
- Nooka, Ajay K
- Pour, Ludek
- Weisel, Katja
- Cavo, Michele
- Laubach, Jacob P